Tissue Heart Valves - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Tissue Heart Valves Market Summary
This tissue heart valves market report offers a comprehensive overview of the global tissue heart valves market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Type (Stented, Stentless, and Sutureles), Valve Position (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Specialty Centers), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing tissue heart valves market.
Tissue heart valves, also known as bioprosthetic heart valves, are artificial replacement valves made from biological tissue typically derived from bovine (cow) pericardium or porcine (pig) heart valves. They are used to replace diseased or damaged native heart valves affected by conditions such as aortic stenosis or mitral regurgitation. These valves are designed to mimic the natural function of the human heart valve and allow one-way blood flow through the heart chambers. Tissue heart valves can be implanted through open-heart surgery or via minimally invasive transcatheter procedures such as TAVR.
The market for tissue heart valves is primarily driven by the rising prevalence of valvular heart diseases, particularly aortic stenosis and mitral regurgitation, along with the rapid expansion of transcatheter procedures such as TAVR. The growing geriatric population, which prefers tissue valves due to the reduced need for lifelong anticoagulation therapy compared to mechanical valves, further supports demand. Additionally, continuous technological advancements that enhance valve durability and enable minimally invasive and valve-in-valve procedures are significantly accelerating market growth worldwide.
Get More Insights into the Report @Tissue Heart Valves Market
What are the latest tissue heart valves market dynamics and trends?
The increasing cases of valvular heart disease, is significantly driving the demand for tissue heart valves.
According to the data provided by the recent studies (2026), aortic stenosis was the most common valvular heart disease in industrialized countries, affecting approximately 10% of individuals over the age of 75, with around 2–4% experiencing severe forms of the condition. Nearly half of those affected were asymptomatic at the time of diagnosis.
Additionally as per the data provided by the DelveInsight Business Research LLP (2026), the population prevalence of aortic stenosis in individuals aged 75 years and older was estimated at 12.4%, with 3.4% experiencing severe aortic stenosis, based on studies conducted predominantly in Europe and the US. As the condition progresses, it leads to narrowing of the aortic valve, restricting blood flow from the heart and ultimately requiring valve replacement in moderate to severe cases. The rapid adoption of minimally invasive procedures such as transcatheter aortic valve replacement (TAVR), which exclusively uses bioprosthetic (tissue) valves, has substantially increased procedural volumes worldwide.
Furthermore, as per the recent studies (2025), the global prevalence of moderate-to-severe mitral regurgitation was 0.67%. Prevalence increased greatly with age, and it was estimated to be approximately 0.63% at age 50, 2.85% at 70, and 6.45% by 90 years. As the mitral valve fails to close properly, backward blood flow leads to symptoms such as fatigue, shortness of breath, and progressive cardiac dysfunction, often necessitating valve repair or replacement in advanced stages. The growing adoption of surgical mitral valve replacement and emerging transcatheter mitral valve replacement (TMVR) procedures both of which commonly utilize bioprosthetic tissue valves has significantly expanded treatment volumes.
Furthermore, the presence of key market players are further escalating the overall market of tissue heart valves. For instance, in April 2024, Medtronic plc, a global leader in healthcare technology, announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra™ valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aortic valve solution that can be fit for the future, right from the start.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves during the forecast period from 2026 to 2034.
However, the tissue heart valve market faces limitations due to the relatively limited durability of bioprosthetic valves, as they are prone to structural valve degeneration and calcification over time, particularly in younger patients. This increases the likelihood of reintervention and long-term treatment costs. Additionally, the high cost of transcatheter procedures such as TAVR restricts accessibility in cost-sensitive and developing regions. Stringent regulatory approval processes, requiring extensive clinical trials and long-term safety data, further delay product launches and increase development expenses, collectively acting as significant restraining factors for market growth.
Tissue Heart Valves Market Segment Analysis
Tissue Heart Valves Market Type of Type (Stented, Stentless, and Sutureles), Valve Position (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Specialty Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Tissue Heart Valves Market Regional Analysis
North America Tissue Heart Valves Market Trends
North America is poised to secure the largest share of 38% in the global tissue heart valves market in 2025 due to the high prevalence of valvular heart diseases, strong adoption of advanced transcatheter procedures such as TAVR, and the presence of leading market players. Favorable reimbursement policies, well-established cardiac care infrastructure, and a rapidly growing elderly population further contribute to the region’s leading market share.
Accorindg to the research provided by the DelveInsight Business Research LLP (2026), more than 13% of Americans aged 75 years and older are affected by aortic stenosis. The condition is also common in individuals over the age of 65, and if left untreated, it can lead to heart failure and death. As the aortic valve becomes narrowed and calcified, blood flow from the heart is restricted, eventually requiring valve replacement in moderate to severe cases. The growing number of elderly patients diagnosed with severe aortic stenosis has led to a substantial increase in both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) procedures, both of which predominantly use bioprosthetic (tissue) valves. The expansion of TAVR into intermediate- and low-risk patient groups has further amplified procedural volumes, directly increasing demand for tissue heart valves across the region.
Furthermore, the increasing product development activities are further boosting the market in North America. For instance, in February 2024, FDA approved Edwards EVOQUE Tricuspid Valve Replacement System. The Edwards EVOQUE Tricuspid Valve Replacement System mainly includes an artificial tricuspid valve (called the EVOQUE valve) and a delivery catheter. The EVOQUE valve is made of cow tissue attached to a self-expanding metal (nickel-titanium) frame for support.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves in North America during the forecasted period.
Europe Tissue Heart Valves Market Trends
Europe is driving the growth of the Tissue Heart Valves market due to its rapidly aging population, high prevalence of valvular heart diseases, and strong adoption of advanced transcatheter procedures such as TAVR. The region benefits from well-established cardiac care infrastructure, early regulatory approvals through CE Mark pathways, and the presence of leading medical device manufacturers. Additionally, favorable reimbursement frameworks and increasing clinical research activities further support higher procedural volumes, making Europe a key contributor to market expansion.
Accorindg to the research provided by the DelveInsight Business Research LLP (2026), in the UK, the point prevalence of severe aortic stenosis among individuals aged 55 years and older was estimated at 1.48% in 2019. Additionally, the estimated prevalence of aortic stenosis in the adult population of France is approximately 1.17%, based on its proportion among all valvular heart disease cases.
With progressive valve narrowing leading to symptoms such as chest pain, breathlessness, and heart failure, timely valve replacement becomes essential for survival in severe cases. Since transcatheter therapies for aortic stenosis exclusively utilize tissue-based valves, the rapid adoption of minimally invasive interventions has significantly accelerated market expansion. Additionally, physicians often prefer tissue valves in elderly aortic stenosis patients to avoid lifelong anticoagulation therapy, further strengthening demand and reinforcing the dominance of this segment in the Europe market.
However, in May 2024, Edwards Lifesciences announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability. Edwards’ SAPIEN 3 Ultra RESILIA valve received CE Mark for use in patients with heart valve disease due to native calcific aortic stenosis at all levels of surgical risk or due to the failure of either a transcatheter or a surgical bioprosthetic valve who are judged to be at high or greater risk for open surgical therapy.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves in Europe.
Asia-Pacific Tissue Heart Valves Market Trends
The Asia-Pacific region is emerging as a key growth driver in the Tissue Heart Valves market due to its rapidly aging population, rising prevalence of valvular heart diseases, and improving access to advanced cardiac care. Increasing healthcare investments, expanding hospital infrastructure, and growing adoption of minimally invasive procedures such as TAVR are accelerating procedural volumes across countries like China, India, and Japan. Additionally, supportive government initiatives and the entry of global as well as regional manufacturers are further strengthening market growth in the region.
However, the increase in product development activites are further boosting the overall market of tissue heart valves. For instance, in September 2025, Edwards Lifesciences launched its next-generation transcatheter heart valve in India for treating aortic stenosis, providing a durable, minimally invasive alternative to open-heart surgery for patients in the Asia-Pacific region. This launch reflected the growing adoption of advanced TAVR therapies in emerging markets.
Thus, the factors mentioned are expected to boost the overall market of tissue heart valves in the Asia-Pacific region during the forecast period.
Who are the major players in the tissue heart valves market?
The following are the leading companies in the tissue heart valves market. These companies collectively hold the largest market share and dictate industry trends.
The competitive landscape of the tissue heart valves market is shaped by a mix of well-established global players and emerging regional innovators, leading to a moderately concentrated yet dynamic environment. Major medical device companies such as Edwards Lifesciences, Medtronic, Abbott Laboratories and Boston Scientific dominate the market by offering comprehensive portfolios of surgical and transcatheter tissue valves across multiple valve positions (aortic, mitral, pulmonary). These companies leverage strong R&D capabilities, extensive clinical evidence, global sales networks, and early regulatory approvals to secure leading market shares, particularly in developed regions such as North America and Europe. Emerging competitors and regional manufacturers especially in the Asia-Pacific market are increasingly gaining traction by introducing cost-competitive devices tailored to local clinical needs and regulatory frameworks. Examples include Meril Life Sciences’ Myval TAVR system and domestic transcatheter valve systems approved in markets like India and Korea. Despite this growing competition, the segment remains relatively concentrated at the top, with the leading players collectively accounting for a substantial portion of global revenues due to their technological advantage, broad indication coverage, and strong physician preference. At the same time, partnerships, mergers, and incremental innovations in durability and minimally invasive technology continue to intensify competitive activity and may gradually diversify market share over the coming years.
Recent Developmental Activities in the Tissue Heart Valves Market
Stentless
Sutureles
Mitral Valve
Pulmonary Valve
Tricuspid Valve
Ambulatory Surgical Centers
Cardiac Specialty Centers
AI-Powered Innovations and Applications:
AI‑powered innovations in tissue heart valves are rapidly advancing both the design and clinical application of these devices by leveraging data, predictive modeling, and automation. Machine learning algorithms are being used to analyze large sets of patient imaging and biomechanical data to optimize valve geometries that better mimic native heart function and reduce stress points that lead to early failure. AI‑driven computational modeling and simulation tools enable virtual testing of valve prototypes under varied physiological conditions, drastically accelerating development cycles and reducing the need for extensive physical testing. In the clinical setting, AI aids in patient selection and personalized treatment planning by integrating patient‑specific risk profiles, anatomical data from CT/MRI, and procedural outcomes to guide whether a tissue valve is appropriate and what size/configuration will perform best. Additionally, advanced AI systems are being developed to predict long‑term valve performance and potential complications such as calcification or degeneration, enabling proactive follow‑up and earlier interventions. Coupled with robotics and augmented reality, AI also supports precision implantation during transcatheter valve procedures by enhancing intraoperative imaging interpretation and navigation, which can improve procedural success rates and reduce operative time. Together, these applications are making tissue heart valve therapy more personalized, efficient, and effective.
U.S. Tariff Impact Analysis on Tissue Heart Valves Market:
The imposition of U.S. tariffs on tissue heart valves and other medical devices has had a noticeable impact on the industry by increasing costs, disrupting established global supply chains, and creating uncertainty for manufacturers and healthcare providers. Since many cardiovascular devices including tissue heart valves and related components are produced or sourced internationally, tariffs raise the cost of imported materials and finished products, which manufacturers may pass on to hospitals and patients, potentially leading to higher healthcare expenses and reduced access to advanced therapies. Tariff‑related cost pressures also risk slowing growth in the U.S. cardiovascular device market by forcing companies to adjust forecasts, absorb expenses, or reconsider investment and pricing strategies, and they contribute to supply chain instability that can delay production and distribution of critical heart valve technologies. In response, some industry stakeholders caution that prolonged trade barriers could dampen innovation and competitiveness unless policies become more stable and supportive of both domestic production and international collaboration.
How This Analysis Helps Clients
1. What is the growth rate of the tissue heart valves market?
- The global tissue heart valves market is expected to increase from USD 10,743.75 million in 2025 to USD 25,307.93 million by 2034, reflecting strong and sustained growth.
- The global tissue heart valves market is growing at a CAGR of 10.08% during the forecast period from 2026 to 2034.
- The market for tissue heart valves is primarily driven by the rising prevalence of valvular heart diseases, particularly aortic stenosis and mitral regurgitation, along with the rapid expansion of transcatheter procedures such as TAVR. The growing geriatric population, which prefers tissue valves due to the reduced need for lifelong anticoagulation therapy compared to mechanical valves, further supports demand. Additionally, continuous technological advancements that enhance valve durability and enable minimally invasive and valve-in-valve procedures are significantly accelerating market growth worldwide.
- The leading companies operating in the tissue heart valves market include Abbott, Boston Scientific Corporation, CryoLife, Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomédica and Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences, Beijing Balance Medical Technology Co., Venus Medtech, others.
- North America is expected to dominate the tissue heart valves market due to the high prevalence of valvular heart diseases, strong adoption of advanced transcatheter procedures such as TAVR, and the presence of leading market players. Favorable reimbursement policies, well-established cardiac care infrastructure, and a rapidly growing elderly population further contribute to the region’s leading market share.
- In the procedure type of devices segment of the tissue heart valves market, the stented category is estimated to account for the largest market share in 2025.
- Rising Prevalence of valvular heart diseases leading to a surge in tissue heart valves: The rising prevalence of valvular heart diseases, particularly aortic stenosis and mitral regurgitation, is significantly increasing the demand for tissue heart valves. As the global population ages and risk factors such as hypertension, diabetes, and rheumatic heart disease remain common, the number of patients requiring valve replacement continues to grow. Tissue heart valves are widely preferred due to their improved durability and reduced need for lifelong anticoagulation, leading to a surge in procedural volumes and overall market expansion.
- Rapid growth of Transcatheter Valve Procedures (TAVR/TAVI) escalating the market of tissue heart valves: The rapid growth of transcatheter valve procedures, particularly Transcatheter Aortic Valve Replacement (TAVR/TAVI), is significantly accelerating the tissue heart valves market. As TAVR is exclusively performed using bioprosthetic (tissue) valves, the expansion of this minimally invasive procedure into intermediate- and low-risk patient groups has substantially increased procedural volumes. Shorter hospital stays, faster recovery times, and reduced surgical risks compared to open-heart surgery have further boosted adoption, directly driving demand for tissue heart valves worldwide.
- Increase in technological advancement: The increase in technological advancements is significantly driving the tissue heart valves market by improving valve durability, safety, and procedural outcomes. Innovations such as enhanced anti-calcification treatments, advanced leaflet designs, sutureless surgical valves, and next-generation transcatheter delivery systems have extended valve lifespan and reduced complications. These improvements increase physician confidence, expand eligibility to younger and lower-risk patients, and ultimately accelerate overall market growth.
This tissue heart valves market report offers a comprehensive overview of the global tissue heart valves market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Type (Stented, Stentless, and Sutureles), Valve Position (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Specialty Centers), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing tissue heart valves market.
Tissue heart valves, also known as bioprosthetic heart valves, are artificial replacement valves made from biological tissue typically derived from bovine (cow) pericardium or porcine (pig) heart valves. They are used to replace diseased or damaged native heart valves affected by conditions such as aortic stenosis or mitral regurgitation. These valves are designed to mimic the natural function of the human heart valve and allow one-way blood flow through the heart chambers. Tissue heart valves can be implanted through open-heart surgery or via minimally invasive transcatheter procedures such as TAVR.
The market for tissue heart valves is primarily driven by the rising prevalence of valvular heart diseases, particularly aortic stenosis and mitral regurgitation, along with the rapid expansion of transcatheter procedures such as TAVR. The growing geriatric population, which prefers tissue valves due to the reduced need for lifelong anticoagulation therapy compared to mechanical valves, further supports demand. Additionally, continuous technological advancements that enhance valve durability and enable minimally invasive and valve-in-valve procedures are significantly accelerating market growth worldwide.
Get More Insights into the Report @Tissue Heart Valves Market
What are the latest tissue heart valves market dynamics and trends?
The increasing cases of valvular heart disease, is significantly driving the demand for tissue heart valves.
According to the data provided by the recent studies (2026), aortic stenosis was the most common valvular heart disease in industrialized countries, affecting approximately 10% of individuals over the age of 75, with around 2–4% experiencing severe forms of the condition. Nearly half of those affected were asymptomatic at the time of diagnosis.
Additionally as per the data provided by the DelveInsight Business Research LLP (2026), the population prevalence of aortic stenosis in individuals aged 75 years and older was estimated at 12.4%, with 3.4% experiencing severe aortic stenosis, based on studies conducted predominantly in Europe and the US. As the condition progresses, it leads to narrowing of the aortic valve, restricting blood flow from the heart and ultimately requiring valve replacement in moderate to severe cases. The rapid adoption of minimally invasive procedures such as transcatheter aortic valve replacement (TAVR), which exclusively uses bioprosthetic (tissue) valves, has substantially increased procedural volumes worldwide.
Furthermore, as per the recent studies (2025), the global prevalence of moderate-to-severe mitral regurgitation was 0.67%. Prevalence increased greatly with age, and it was estimated to be approximately 0.63% at age 50, 2.85% at 70, and 6.45% by 90 years. As the mitral valve fails to close properly, backward blood flow leads to symptoms such as fatigue, shortness of breath, and progressive cardiac dysfunction, often necessitating valve repair or replacement in advanced stages. The growing adoption of surgical mitral valve replacement and emerging transcatheter mitral valve replacement (TMVR) procedures both of which commonly utilize bioprosthetic tissue valves has significantly expanded treatment volumes.
Furthermore, the presence of key market players are further escalating the overall market of tissue heart valves. For instance, in April 2024, Medtronic plc, a global leader in healthcare technology, announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra™ valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aortic valve solution that can be fit for the future, right from the start.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves during the forecast period from 2026 to 2034.
However, the tissue heart valve market faces limitations due to the relatively limited durability of bioprosthetic valves, as they are prone to structural valve degeneration and calcification over time, particularly in younger patients. This increases the likelihood of reintervention and long-term treatment costs. Additionally, the high cost of transcatheter procedures such as TAVR restricts accessibility in cost-sensitive and developing regions. Stringent regulatory approval processes, requiring extensive clinical trials and long-term safety data, further delay product launches and increase development expenses, collectively acting as significant restraining factors for market growth.
Tissue Heart Valves Market Segment Analysis
Tissue Heart Valves Market Type of Type (Stented, Stentless, and Sutureles), Valve Position (Aortic Valve, Mitral Valve, Pulmonary Valve, and Tricuspid Valve), End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Specialty Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Tissue Heart Valves Market Regional Analysis
North America Tissue Heart Valves Market Trends
North America is poised to secure the largest share of 38% in the global tissue heart valves market in 2025 due to the high prevalence of valvular heart diseases, strong adoption of advanced transcatheter procedures such as TAVR, and the presence of leading market players. Favorable reimbursement policies, well-established cardiac care infrastructure, and a rapidly growing elderly population further contribute to the region’s leading market share.
Accorindg to the research provided by the DelveInsight Business Research LLP (2026), more than 13% of Americans aged 75 years and older are affected by aortic stenosis. The condition is also common in individuals over the age of 65, and if left untreated, it can lead to heart failure and death. As the aortic valve becomes narrowed and calcified, blood flow from the heart is restricted, eventually requiring valve replacement in moderate to severe cases. The growing number of elderly patients diagnosed with severe aortic stenosis has led to a substantial increase in both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) procedures, both of which predominantly use bioprosthetic (tissue) valves. The expansion of TAVR into intermediate- and low-risk patient groups has further amplified procedural volumes, directly increasing demand for tissue heart valves across the region.
Furthermore, the increasing product development activities are further boosting the market in North America. For instance, in February 2024, FDA approved Edwards EVOQUE Tricuspid Valve Replacement System. The Edwards EVOQUE Tricuspid Valve Replacement System mainly includes an artificial tricuspid valve (called the EVOQUE valve) and a delivery catheter. The EVOQUE valve is made of cow tissue attached to a self-expanding metal (nickel-titanium) frame for support.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves in North America during the forecasted period.
Europe Tissue Heart Valves Market Trends
Europe is driving the growth of the Tissue Heart Valves market due to its rapidly aging population, high prevalence of valvular heart diseases, and strong adoption of advanced transcatheter procedures such as TAVR. The region benefits from well-established cardiac care infrastructure, early regulatory approvals through CE Mark pathways, and the presence of leading medical device manufacturers. Additionally, favorable reimbursement frameworks and increasing clinical research activities further support higher procedural volumes, making Europe a key contributor to market expansion.
Accorindg to the research provided by the DelveInsight Business Research LLP (2026), in the UK, the point prevalence of severe aortic stenosis among individuals aged 55 years and older was estimated at 1.48% in 2019. Additionally, the estimated prevalence of aortic stenosis in the adult population of France is approximately 1.17%, based on its proportion among all valvular heart disease cases.
With progressive valve narrowing leading to symptoms such as chest pain, breathlessness, and heart failure, timely valve replacement becomes essential for survival in severe cases. Since transcatheter therapies for aortic stenosis exclusively utilize tissue-based valves, the rapid adoption of minimally invasive interventions has significantly accelerated market expansion. Additionally, physicians often prefer tissue valves in elderly aortic stenosis patients to avoid lifelong anticoagulation therapy, further strengthening demand and reinforcing the dominance of this segment in the Europe market.
However, in May 2024, Edwards Lifesciences announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability. Edwards’ SAPIEN 3 Ultra RESILIA valve received CE Mark for use in patients with heart valve disease due to native calcific aortic stenosis at all levels of surgical risk or due to the failure of either a transcatheter or a surgical bioprosthetic valve who are judged to be at high or greater risk for open surgical therapy.
Thus, the factors mentioned above are expected to boost the overall market of tissue heart valves in Europe.
Asia-Pacific Tissue Heart Valves Market Trends
The Asia-Pacific region is emerging as a key growth driver in the Tissue Heart Valves market due to its rapidly aging population, rising prevalence of valvular heart diseases, and improving access to advanced cardiac care. Increasing healthcare investments, expanding hospital infrastructure, and growing adoption of minimally invasive procedures such as TAVR are accelerating procedural volumes across countries like China, India, and Japan. Additionally, supportive government initiatives and the entry of global as well as regional manufacturers are further strengthening market growth in the region.
However, the increase in product development activites are further boosting the overall market of tissue heart valves. For instance, in September 2025, Edwards Lifesciences launched its next-generation transcatheter heart valve in India for treating aortic stenosis, providing a durable, minimally invasive alternative to open-heart surgery for patients in the Asia-Pacific region. This launch reflected the growing adoption of advanced TAVR therapies in emerging markets.
Thus, the factors mentioned are expected to boost the overall market of tissue heart valves in the Asia-Pacific region during the forecast period.
Who are the major players in the tissue heart valves market?
The following are the leading companies in the tissue heart valves market. These companies collectively hold the largest market share and dictate industry trends.
- Abbott
- Boston Scientific Corporation
- CryoLife
- Edward Lifesciences Corporation
- Medtronic
- Sorin Group (LivaNova PLC)
- Braile Biomédica and Labcor Laboratórios
- Colibri Heart Valve
- ON-X LIFE TECHNOLOGIES
- JenaValve Technology Inc.
- TTK Healthcare Limited
- Comed BV
- Meril Life Sciences
- Beijing Balance Medical Technology Co.
- Venus Medtech
- Others
The competitive landscape of the tissue heart valves market is shaped by a mix of well-established global players and emerging regional innovators, leading to a moderately concentrated yet dynamic environment. Major medical device companies such as Edwards Lifesciences, Medtronic, Abbott Laboratories and Boston Scientific dominate the market by offering comprehensive portfolios of surgical and transcatheter tissue valves across multiple valve positions (aortic, mitral, pulmonary). These companies leverage strong R&D capabilities, extensive clinical evidence, global sales networks, and early regulatory approvals to secure leading market shares, particularly in developed regions such as North America and Europe. Emerging competitors and regional manufacturers especially in the Asia-Pacific market are increasingly gaining traction by introducing cost-competitive devices tailored to local clinical needs and regulatory frameworks. Examples include Meril Life Sciences’ Myval TAVR system and domestic transcatheter valve systems approved in markets like India and Korea. Despite this growing competition, the segment remains relatively concentrated at the top, with the leading players collectively accounting for a substantial portion of global revenues due to their technological advantage, broad indication coverage, and strong physician preference. At the same time, partnerships, mergers, and incremental innovations in durability and minimally invasive technology continue to intensify competitive activity and may gradually diversify market share over the coming years.
Recent Developmental Activities in the Tissue Heart Valves Market
- In September 2025, Edwards Lifesciences launched its next-generation transcatheter heart valve in India for treating aortic stenosis, providing a durable, minimally invasive alternative to open-heart surgery for patients in the Asia-Pacific region. This launch reflected the growing adoption of advanced TAVR therapies in emerging markets.
- Tissue Heart Valves by Type Exposure
Stentless
Sutureles
- Tissue Heart Valves Valves Position Exposure
Mitral Valve
Pulmonary Valve
Tricuspid Valve
- Tissue Heart Valves End-Users Exposure
Ambulatory Surgical Centers
Cardiac Specialty Centers
- Tissue Heart Valves Geography Exposure
- United States Tissue Heart Valves Market
- Canada Tissue Heart Valves Market
- Mexico Tissue Heart Valves Market
- United Kingdom Tissue Heart Valves Market
- Germany Tissue Heart Valves Market
- France Tissue Heart Valves Market
- Italy Tissue Heart Valves Market
- Spain Tissue Heart Valves Market
- Rest of Europe Tissue Heart Valves Market
- China Tissue Heart Valves Market
- Japan Tissue Heart Valves Market
- India Tissue Heart Valves Market
- Australia Tissue Heart Valves Market
- South Korea Tissue Heart Valves Market
- Rest of Asia-Pacific Tissue Heart Valves Market
- South America Tissue Heart Valves Market
- Middle East Tissue Heart Valves Market
- Africa Tissue Heart Valves Market
AI-Powered Innovations and Applications:
AI‑powered innovations in tissue heart valves are rapidly advancing both the design and clinical application of these devices by leveraging data, predictive modeling, and automation. Machine learning algorithms are being used to analyze large sets of patient imaging and biomechanical data to optimize valve geometries that better mimic native heart function and reduce stress points that lead to early failure. AI‑driven computational modeling and simulation tools enable virtual testing of valve prototypes under varied physiological conditions, drastically accelerating development cycles and reducing the need for extensive physical testing. In the clinical setting, AI aids in patient selection and personalized treatment planning by integrating patient‑specific risk profiles, anatomical data from CT/MRI, and procedural outcomes to guide whether a tissue valve is appropriate and what size/configuration will perform best. Additionally, advanced AI systems are being developed to predict long‑term valve performance and potential complications such as calcification or degeneration, enabling proactive follow‑up and earlier interventions. Coupled with robotics and augmented reality, AI also supports precision implantation during transcatheter valve procedures by enhancing intraoperative imaging interpretation and navigation, which can improve procedural success rates and reduce operative time. Together, these applications are making tissue heart valve therapy more personalized, efficient, and effective.
U.S. Tariff Impact Analysis on Tissue Heart Valves Market:
The imposition of U.S. tariffs on tissue heart valves and other medical devices has had a noticeable impact on the industry by increasing costs, disrupting established global supply chains, and creating uncertainty for manufacturers and healthcare providers. Since many cardiovascular devices including tissue heart valves and related components are produced or sourced internationally, tariffs raise the cost of imported materials and finished products, which manufacturers may pass on to hospitals and patients, potentially leading to higher healthcare expenses and reduced access to advanced therapies. Tariff‑related cost pressures also risk slowing growth in the U.S. cardiovascular device market by forcing companies to adjust forecasts, absorb expenses, or reconsider investment and pricing strategies, and they contribute to supply chain instability that can delay production and distribution of critical heart valve technologies. In response, some industry stakeholders caution that prolonged trade barriers could dampen innovation and competitiveness unless policies become more stable and supportive of both domestic production and international collaboration.
How This Analysis Helps Clients
- Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
- Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
- Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
- Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
- Market size analysis for the current tissue heart valves market size (2025), and market forecast for 8 years (2026 to 2034)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key companies dominating the tissue heart valves market.
- Various opportunities available for the other competitors in the tissue heart valves market space.
- What are the top-performing segments in 2025? How these segments will perform in 2034?
- Which are the top-performing regions and countries in the current tissue heart valves market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for the tissue heart valves market growth in the future?
1. What is the growth rate of the tissue heart valves market?
- The tissue heart valves market is estimated to grow at a CAGR of 10.08% during the forecast period from 2026 to 2034.
- The global tissue heart valves market is expected to increase from USD 10,743.75 million in 2025 to USD 25,307.93 million by 2034.
- North America is expected to dominate the tissue heart valves market due to the high prevalence of valvular heart diseases, strong adoption of advanced transcatheter procedures such as TAVR, and the presence of leading market players. Favorable reimbursement policies, well-established cardiac care infrastructure, and a rapidly growing elderly population further contribute to the region’s leading market share.
- The market for tissue heart valves is primarily driven by the rising prevalence of valvular heart diseases, particularly aortic stenosis and mitral regurgitation, along with the rapid expansion of transcatheter procedures such as TAVR. The growing geriatric population, which prefers tissue valves due to the reduced need for lifelong anticoagulation therapy compared to mechanical valves, further supports demand. Additionally, continuous technological advancements that enhance valve durability and enable minimally invasive and valve-in-valve procedures are significantly accelerating market growth worldwide.
- Some of the key market players operating in the tissue heart valves market include Abbott, Boston Scientific Corporation, CryoLife, Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomédica and Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences, Beijing Balance Medical Technology Co., Venus Medtech, and others.
Table of Contents
150 Pages
- 1. Tissue Heart Valves Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumption
- 2. Tissue Heart Valves Market Executive Summary
- 2.1 Market at Glance
- 3. Tissue Heart Valves Market Key Factors Analysis
- 3.1 Tissue Heart Valves Market Drivers
- 3.1.1 Rising Prevalence of valvular heart diseases leading to a surge in tissue heart valves
- 3.1.2 Rapid growth of Transcatheter Valve Procedures (TAVR/TAVI) escalating the market of tissue heart valves
- 3.1.3 Increase in technological advancement
- 3.2 Tissue Heart Valves Market Restraints and Challenges
- 3.2.1 Limited durability and risk of calcification
- 3.2.2 Stringent regulatory process for product approval
- 3.3 Tissue Heart Valves Market Opportunity
- 3.3.1 Integration of advanced imaging, AI‑driven diagnostics, and robotic assistance
- 4. Impact Analysis
- 4.1 AI-Powered Innovations and Applications
- 4.2 U.S. Tariff Impact Analysis
- 5. Regulatory Analysis
- 5.1 The United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
- 6. Tissue Heart Valves Market Porter’s Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Consumers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
- 7. Tissue Heart Valves Market Assessment
- 7.1 By Type
- 7.1.1 Stented
- 7.1.2 Stentless
- 7.1.3 Sutureles
- 7.2 By Valve Position
- 7.2.1 Aortic Valve
- 7.2.2 Mitral Valve
- 7.2.3 Pulmonary Valve
- 7.2.4 Tricuspid Valve
- 7.3 By End-Users
- 7.3.1 Hospitals
- 7.3.2 Ambulatory Surgical Centers
- 7.3.3 Cardiac Specialty Centers
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 France Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2.2 Germany Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2.3 United Kingdom Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3.3 India Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.4 Rest of the World (RoW)
- 7.4.4.1 Middle East Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Tissue Heart Valves Market Size in USD million (2023-2034)
- 7.4.4.3 South America Tissue Heart Valves Market Size In USD Million (2023-2034)
- 8. Competitive Landscape
- 9. Startup Funding & Investment Trends
- 10. Tissue Heart Valves Market Company and Product Profiles
- 10.1 Abbott
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Product Listing
- 10.1.5 Entropy
- 10.2 Boston Scientific Corporation
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Listing
- 10.2.5 Entropy
- 10.3 CryoLife
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Listing
- 10.3.5 Entropy
- 10.4 Edward Lifesciences Corporation
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Listing
- 10.4.5 Entropy
- 10.5 Medtronic
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Listing
- 10.5.5 Entropy
- 10.6 Sorin Group (LivaNova PLC)
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Listing
- 10.6.5 Entropy
- 10.7 Braile Biomédica and Labcor Laboratórios
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Listing
- 10.7.5 Entropy
- 10.8 Colibri Heart Valve
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Listing
- 10.8.5 Entropy
- 10.9 ON-X LIFE TECHNOLOGIES
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Listing
- 10.9.5 Entropy
- 10.10 JenaValve Technology Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Listing
- 10.10.5 Entropy
- 10.11 TTK Healthcare Limited
- 10.11.1 Company Overview
- 10.11.2 Company Snapshot
- 10.11.3 Financial Overview
- 10.11.4 Product Listing
- 10.11.5 Entropy
- 10.12 Comed BV
- 10.12.1 Company Overview
- 10.12.2 Company Snapshot
- 10.12.3 Financial Overview
- 10.12.4 Product Listing
- 10.12.5 Entropy
- 10.13 Meril Life Sciences
- 10.13.1 Company Overview
- 10.13.2 Company Snapshot
- 10.13.3 Financial Overview
- 10.13.4 Product Listing
- 10.13.5 Entropy
- 10.14 Beijing Balance Medical Technology Co.
- 10.14.1 Company Overview
- 10.14.2 Company Snapshot
- 10.14.3 Financial Overview
- 10.14.4 Product Listing
- 10.14.5 Entropy
- 10.15 Venus Medtech
- 10.15.1 Company Overview
- 10.15.2 Company Snapshot
- 10.15.3 Financial Overview
- 10.15.4 Product Listing
- 10.15.5 Entropy
- 11. KOL Views
- 12. Project Approach
- 13. About DelveInsight
- 14. Disclaimer & Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
